Biogen Reports Phase 2 Data for Mepolizumab in IgA nephropathy

Biogen today announced Phase 2 results for Mepolizumab in patients with IgA nephropathy. The study demonstrated that Mepolizumab demonstrates superior efficacy vs standard of care compared to standard of care or placebo. These results provide important insights into the treatment of IgA nephropathy and support the continued development of Mepolizumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Mepolizumab was consistent with previous observations, with no new safety signals identified.